

10 March 2025



Eden Research plc
("Eden" or "the Company")

Appointment of Joint Broker

Eden Research plc (AIM: EDEN), a leader in sustainable biopesticide and biocontrol technology, is pleased to announce the appointment of Oberon Capital ("Oberon") as its joint broker with immediate effect. Oberon will act alongside Cavendish Capital Markets to enhance brokerage services.

Oberon Capital is an independent investment bank with a specialist focus on London's growth markets, led by a team of veteran brokers with a wealth of experience across multiple sectors. The firm's appointment is intended to increase Eden's profile with a new audience of potential investors, build share register strength and improve share liquidity.

Sean Smith, Chief Executive Officer of Eden Research, commented:

"We are pleased to appoint Oberon as a joint broker, working closely with Cavendish. As many AIM investors know all too well, in the current climate companies such as Eden have struggled with liquidity and attracting the attention of new investors. We expect Oberon to play an important role in the Company's future as we seek to increase our exposure to new investors who value the Company's growing business and its alignment with regulatory imperatives affecting the agriculture industry across Europe and globally."

-- ENDS --

For further information contact:

Eden Research plc

Sean Smith
Alex Abrey

www.edenresearch.com
01285 359 555

Cavendish Capital Markets Limited **(Nominated advisor and joint broker)**

Giles Balleny / George Lawson (corporate finance)
Charlie Combe (corporate broking)
Michael Johnson (sales)

020 7220 0500

Oberon Capital (Joint broker)

Nick Lovering
Mike Seabrook
Adam Pollock

020 3179 5300

Hawthorn Advisors (Financial PR)

Victoria Ainsworth

eden@hawthornadvisors.com

Notes to Editors:

Eden Research is the only UK-listed company focused on biopesticides for sustainable agriculture. It develops and supplies innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries.

Eden's products are formulated with terpene active ingredients, based on natural plant defence metabolites. To date, they have been primarily used on high-value fruits and vegetables, improving crop yields and marketability, with equal or better performance when compared with conventional pesticides. Eden has three products currently on the market:

Based on plant-derived active ingredients, **Mevalone**[®] is a foliar biofungicide which initially targets a key disease affecting grapes and other high-value fruit and vegetable crops. It is a useful tool in crop defence programmes and is aligned with the requirements of integrated pest management programmes. It is approved for sale in a number of key countries whilst Eden and its partners pursue regulatory clearance in new territories thereby growing Eden's addressable market globally.

Novellus[®] is an evolution of Mevalone, allowing improved rates in the field, high levels of efficacy and a broader list of targets.

Cedroz[™] is a bionematicide that targets free living nematodes which are parasitic worms that affect a wide range of high-value fruit and vegetable crops globally. Cedroz is registered for sale on two continents and Eden's commercial collaborator, Eastman Chemical, is pursuing registration and commercialisation of this important new product in numerous countries globally.

Eden's seed treatment product, **Ecovelex**[™] was developed to safely tackle crop destruction caused by birds - a major cause of losses in maize and other crops. Ecovelex works by creating an unpleasant taste or odour that repels birds, leaving the seeds

safely intact and the birds unaffected and free to find alternative food sources. The product is based on Eden's plant-derived chemistry, registered in the EU, U.S. and elsewhere, and formulated using Eden's Sustaine[®] microencapsulation system.

Eden's Sustaine[®] encapsulation technology is used to harness the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease of use. Sustaine microcapsules are naturally-derived, plastic-free, biodegradable micro-spheres derived from yeast. It is one of the only viable, proven and immediately registerable solutions to the microplastics problem in formulations requiring encapsulation.

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN. It was awarded the London Stock Exchange **Green Economy Mark** in January 2021, which recognises London-listed companies that derive over 50% of their total annual revenue from products and services that contribute to the global green economy. Eden derives 100% of its total annual revenues from sustainable products and services.

For more information about Eden, please visit: www.edenresearch.com. You can also follow Eden's latest developments via its social media channels: [X \(Twitter\)](#) and [LinkedIn](#).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

APPPFFVLVFIAIIE